InnoStudio Continues To Push Chemistry Towards The Stars
Space Chemistry Special Session to be held at International Astronautical Congress for first time
BUDAPEST, Hungary and BOSTON, May 10, 2018 (GLOBE NEWSWIRE) -- InnoStudio is pleased to announce that its proposal for holding a Special Session on Space Chemistry at the 69th International Astronautical Congress entitled "Space Chemistry: a Key to Fostering Space Exploration" has been accepted. This is the first time that a special session on this topic will be held at such a prestigious event. The congress will take place in Bremen, Germany between the 1st and 5th October 2018. The above special session will be held as part of the technical programme. We believe that the acceptance of this topic as a special session greatly emphasizes the importance of Space Chemistry for the future of the Space Industry.
IAC2018 Special Sessions are to supplement the regular technical programme of the congress and provide a sample of the state-of-the-art research and development in both academia and industry in special, novel, challenging and emerging topics in the field of space. Special Sessions emphasize multi-disciplinary and transversal aspects, as well as cutting-edge topics of space exploration.
The list of accepted Special Sessions can be found at http://www.iafastro.org/events/iac/iac- 2018/technical-programme/special-sessions/.
We are also happy to announce that InnoStudio's experts will give a presentation at the 3rd Space Chemistry Symposium - "Chemistry in Space & Past, Present & Future", which will be held on the 254th ACS National Meeting & Exposition between 19th and 23rd August 2018 in Boston, US.
The topics of the symposium will cover a wide range of pioneering chemistry technologies from space perspectives, including flow chemistry, nanomaterials and new platforms for microgravity research onboard the International Space Station. These innovations are expected to make an essential contribution towards facilitating space exploration missions and human expeditions.
Finally, a perspective article written by InnoStudio's space experts was published in the Journal of Flow Chemistry. The paper summarizes the state of the art of space chemistry, analyzes the suitability of flow chemistry in an extraterrestrial environment, and discusses some of the challenges and opportunities in space chemistry.
Read the article here: https://akademiai.com/doi/pdf/10.1556/1846.2017.00033
For more information please contact Richard Jones, CEO: firstname.lastname@example.org
About InnoStudio Inc.
InnoStudio Inc. was founded in 2013 as a spin-off of Cominnex Inc. The companies belong to Darholding, which is a leading innovation house specialized on innovative spin-out companies. The three pillars of success are: a strong scientific background, a wide network of relationships with top companies and a special management approach.
InnoStudio Inc. is specialized in innovating on high risk, high gain fields with high importance such as:
· Nanotechnology: applying dynamic flow systems for generating nanoparticles, primarily for life science and chemistry related fields. e.g. Innostudio formulates first-tier agrochemical substances in collaboration with Agrothetis Inc.
· Artificial Intelligence and Chemometrics: adapting them for developing software solutions needed by sister corporations in the Darholding network and other users for pharma and bioscience related discovery, flow chemistry, microfluidics and nanotechnology.
· Improving bioavailability of natural products: adapting complex physicochemical solutions, including nanotechnology, for enhancing and optimizing skin penetration of natural products in aromatherapy, cosmetics and other flavour and fragrance fields.
· Space Chemistry: bringing experimental chemistry to space by incubating a research and development team of specialists.
Together with two other companies of the Darholding network, ThalesNano Inc. and ComInnex Inc. the Space Chemistry Studio of InnoStudio is working on the Space Chemistry Project for shaping the future of chemistry in space. The Space Chemistry Project was founded by the Flow Chemistry Society on Switzerland in 2014 for bringing chemistry to the space. Today it has more than 40 members from 5 continents. (http://spaceflow.org/)
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: InnoStudio Inc. via Globenewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
AMG Advanced Metallurgical Group N.V. Announces Weekly Share Repurchase Program Transaction Details19.7.2019 21:00:00 CEST | Press release
Amsterdam, 19 July 2019 --- AMG Advanced Metallurgical Group N.V. ("AMG", EURONEXT AMSTERDAM: "AMG") reports the repurchases made under its share repurchase program announced on 8 April 2019 and effective from 9 April 2019. Information regarding the progress of the share repurchase program and the aggregate of the transactions (calculated on a daily basis) for the period 15 July 2019 through 19 July 2019 can be found in the bottom half of the table below. Further detailed information regarding both the progress of the share repurchase program and the overall trades made on a daily basis can be accessed via the Investors section of the Company’s website, or clicking the following link: https://amg-nv.com/investors/share-buyback/ Share Repurchase Program Overall progress Share Repurchase Program: Total Repurchase Amount in Shares 2,915,630 Cumulative Repurchase Amount EUR 63,511,098 Cumulative Quantity Repurchased 2,534,054 Cumulative Average Repurchase Price EUR 25.06 Start Date 9 April
Ossur Hf : Össur acquires College Park Industries19.7.2019 17:00:00 CEST | Press release
Reykjavik, 19 July 2019 Össur has signed an agreement to acquire College Park Industries, a global provider of lower and upper limb prostheses and supporting services. College Park has over 140 employees and is headquartered in Detroit, USA. Total sales amounted to USD 22 million in 2018. College Park will largely remain independent and continue to diligently serve its customer base, while allowing the combined entity to achieve strategic efficiencies. Össur is committed to growing the College Park brand over the coming years both in the United States and international markets. Together, both companies will be well-positioned to enhance their offerings in both lower and upper limb prosthetics. With this acquisition, Össur hopes to support College Park’s focus on the lower active population and further strengthen its established presence in the upper limb arena. Mutual access to technology and products will enable a more comprehensive product and service offering to customers around the
Banks net position in the Riksbank19.7.2019 16:47:00 CEST | Press release
JUL 19, 2019 SEK MILLION LENDING BORROWING 277
Norsk Hydro: PÅMINNELSE: Invitasjon - Presentasjon av Hydros resultat for andre kvartal 201919.7.2019 14:43:00 CEST | Pressemelding
Hydros resultat for andre kvartal 2019 blir offentliggjort tirsdag 23. juli 2019 kl. 07.00. Kvartalsrapporten og presentasjonsmaterialet blir samtidig gjort tilgjengelig på www.hydro.com. Presentasjon i Oslo Det blir holdt en kombinert analytikerpresentasjon og pressekonferanse ved Hydros hovedkontor i Drammensveien 260, Oslo, samme dag, kl. 08.30. Resultatet blir presentert av konsernsjef Hilde Merete Aasheim og konserndirektør for Økonomi og finans Eivind Kallevik. Hele presentasjonen kan sees direkte på web-TV. For påmelding, vennligst send mail til email@example.com. I tillegg til web-TV, hvor det vil være mulig å stille spørsmål skriftlig, vil det også være mulig å ringe inn (ikke mulig å stille spørsmål over telefon). Du melder deg på denne telefonkonferansen ved å ringe: Norge +47 2100 2610 UK +44 (0)330 336 9125 USA +1 929-477-0324 Sverige +46 (0)8 5033 6574 Brasil +55 11 3181 5427 Tyskland +49 (0)89 20303 5709 Kode: 3104804 Q&A / Telefonkonferanse Det blir holdt en telefonkonferans
Norsk Hydro: REMINDER: Invitation - Hydro’s second quarter results 201919.7.2019 14:43:00 CEST | Press release
Hydro's second quarter results 2019 will be released at 07:00 CEST (01:00 AM EDT, 06:00 UK time), on Tuesday July 23, 2019. The quarterly report and presentation slides will be available on www.hydro.com at the same time. Presentation in Oslo Hydro will host a combined analyst and press conference, in English, at its corporate headquarters at Drammensveien 260, Oslo, at 08:30 CEST the same day. The presentation will be held by President and CEO Hilde Merete Aasheim and CFO Eivind Kallevik and can also be seen on web TV. To attend the presentation in Oslo, please register by sending a mail to firstname.lastname@example.org. In addition to the webcast, where it will be possible to ask questions in writing, it will also be possible to dial in (not possible to ask questions over the phone). Dial-in numbers for this conference call are: Norway +47 2100 2610 UK +44 (0)330 336 9125 USA +1 929-477-0324 Sweden +46 (0)8 5033 6574 Brazil +55 11 3181 5427 Germany +49 (0)89 20303 5709 Confirmation Code: 3104804 Q&A
Sunstone Life Science Ventures invests in Karolinska Development's portfolio company Forendo Pharma19.7.2019 14:00:00 CEST | Pressemelding
STOCKHOLM – July 19, 2019. Karolinska Development's portfolio company Forendo Pharma announces today that Sunstone Life Science Ventures joins the existing international investor syndicate and has made a EUR 5 million investment in Forendo Pharma. Claus Andersson, General Partner from Sunstone, joins Forendo Pharma’s Board of Directors. With the investment, Sunstone joins the existing international investor syndicate comprising Novo Seeds, Karolinska Development, Innovestor, Novartis Venture Fund, M Ventures and Vesalius Biocapital Partners. The new financing will enable Forendo Pharma to progress its lead endometriosis program, FOR-6219, an HSD17B1 enzyme inhibitor, into the next phase of clinical studies after the successful completion of its Phase 1a study earlier this year. Endometriosis is a chronic condition that affects many women of reproductive age and causes repeated pain symptoms, infertility and impaired quality of life. Currently available treatments for endometriosis have